RPRX (Royalty Pharma plc Class A Ordinary Shares)
Insider Trading Activity
Every open-market purchase and sale reported by RPRX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-19 | Christopher Hite | EVP & Chairman, Partnering | MIXED | — | — |
| 2026-08-17 | Terrance P. Coyne | EVP & CFO | Sell | — | — |
| 2026-08-07 | Christopher Hite | EVP & Chairman, Partnering | A | — | — |
| 2026-08-07 | Marshall Urist | EVP, Research & Investments | A | — | — |
| 2026-08-07 | Pablo G. Legorreta | CEO, Chairman of the Board | A | — | — |
| 2026-08-07 | Terrance P. Coyne | EVP & CFO | A | — | — |
| 2026-08-07 | Marshall Urist | EVP, Research & Investments | A | — | — |
| 2026-08-07 | Terrance P. Coyne | EVP & CFO | A | — | — |
| 2026-08-07 | Pablo G. Legorreta | CEO, Chairman of the Board | A | — | — |
| 2026-08-07 | Christopher Hite | EVP & Chairman, Partnering | A | — | — |
| 2026-07-02 | Christopher Hite | EVP & Chairman, Partnering | Sell | — | — |
| 2026-07-02 | Marshall Urist | EVP, Research & Investments | Sell | — | — |
| 2026-06-25 | Marshall Urist | EVP, Research & Investments | Sell | — | — |
| 2026-06-25 | Christopher Hite | EVP & Chairman, Partnering | Sell | — | — |
| 2026-06-08 | DAVID C HODGSON | Director | A | — | — |
| 2026-06-08 | TED W LOVE | Director | A | — | — |
| 2026-06-08 | Carole Ho | Director | A | — | — |
| 2026-06-08 | Gregory Norden | Director | A | — | — |
| 2026-06-08 | Bonnie L Bassler | Director | A | — | — |
| 2026-06-08 | Catherine M. Engelbert | Director | A | — | — |
| 2026-06-08 | Vlad Coric | Director | A | — | — |
| 2026-06-08 | ELIZABETH H WEATHERMAN | Director | A | — | — |
| 2026-05-28 | Terrance P. Coyne | EVP & CFO | Sell | — | — |
| 2026-05-21 | Marshall Urist | EVP, Research & Investments | Sell | — | — |
| 2026-05-15 | Gregory Norden | Director | Sell | — | — |
| 2026-05-15 | Marshall Urist | EVP, Research & Investments | Sell | — | — |
| 2026-05-08 | Marshall Urist | EVP, Research & Investments | A | — | — |
| 2026-05-08 | Christopher Hite | EVP & Vice Chairman | A | — | — |
| 2026-05-08 | Terrance P. Coyne | EVP & CFO | A | — | — |
| 2026-05-08 | Pablo G. Legorreta | CEO, Chairman of the Board | A | — | — |
| 2026-04-30 | Terrance P. Coyne | EVP & CFO | Sell | — | — |
| 2026-04-02 | Terrance P. Coyne | EVP & CFO | Sell | — | — |
| 2026-03-31 | Bonnie L Bassler | Director | A | — | — |
| 2026-03-25 | Terrance P. Coyne | EVP & CFO | Sell | — | — |
| 2026-03-04 | Terrance P. Coyne | EVP & CFO | Sell | — | — |
| 2026-02-25 | Terrance P. Coyne | EVP & CFO | Sell | — | — |
| 2026-02-13 | Marshall Urist | EVP, Research & Investments | A | — | — |
| 2026-02-13 | Christopher Hite | EVP & Vice Chairman | A | — | — |
| 2026-02-13 | Terrance P. Coyne | EVP & CFO | A | — | — |
| 2026-02-13 | Pablo G. Legorreta | CEO, Chairman of the Board | A | — | — |
| 2026-02-04 | Terrance P. Coyne | EVP & CFO | Sell | — | — |
| 2026-02-02 | Marshall Urist | EVP, Research & Investments | Sell | — | — |
| 2026-01-26 | Marshall Urist | EVP, Research & Investments | Sell | — | — |
| 2026-01-23 | Terrance P. Coyne | EVP & CFO | Sell | — | — |
| 2026-01-20 | Marshall Urist | EVP, Research & Investments | Sell | — | — |
| 2026-01-13 | Marshall Urist | EVP, Research & Investments | Sell | — | — |
| 2026-01-06 | Marshall Urist | EVP, Research & Investments | Sell | — | — |
| 2026-01-06 | Terrance P. Coyne | EVP & CFO | Sell | — | — |
| 2026-01-02 | Bonnie L Bassler | Director | A | — | — |
| 2025-12-29 | Marshall Urist | EVP, Research & Investments | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 46,015,330 | — |
| — | 10%+ Owner | 38,714,280 | — |
| — | 10%+ Owner | 22,924,176 | — |
| — | 10%+ Owner | 22,657,815 | — |
| — | 10%+ Owner | 22,232,747 | — |
| — | 10%+ Owner | 21,426,170 | — |
| — | Director | 7,802,819 | — |
| — | 10%+ Owner | 7,795,072 | — |
| — | Director | 1,506,597 | — |
| — | CEO, Chairman of the Board | 1,426,320 | — |
| — | EVP, Investments & CLO | 496,090 | — |
| — | Director | 405,286 | — |
| — | EVP & Chairman, Partnering | 393,601 | — |
| — | Director | 196,348 | — |
| — | Director | 123,524 | — |
| — | Director | 81,352 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RPRX quote page; the site-wide leaderboard is on the insider transactions hub.